Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toremifene in Desmoid Tumor
NCT02353429Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toremifene in desmoid-type fibromatosis (DF), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Time to progression at 2 years. Status: unknown.
02
Drugs
toremifene
03
Conditions
desmoid-type fibromatosis (DF)
Beyond the preview
Go deeper on NCT02353429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353429.